Overview

Corneal Versus Conjunctival Delivery Using a Delivery Device

Status:
Withdrawn
Trial end date:
1969-12-31
Target enrollment:
0
Participant gender:
All
Summary
Compare the antihypertensive efficacy of three methods for installing Xalatan
Phase:
Phase 2
Accepts Healthy Volunteers?
No
Details
Lead Sponsor:
Pfizer
Pfizer's Upjohn has merged with Mylan to form Viatris Inc.
Treatments:
Latanoprost
Criteria
Inclusion Criteria:

- Diagnosis of primary open angle glaucoma or ocular hypertension in 1 or both eyes

Exclusion Criteria:

- History of closed/barely open anterior chamber angle or a history of angle closure